Effects of Vitamin D Supplementation on Cognitive and Emotional Functioning in Young Adults – A Randomised Controlled Trial

Queensland Brain Institute, The University of Queensland, St Lucia, Australia.
PLoS ONE (Impact Factor: 3.23). 11/2011; 6(11):e25966. DOI: 10.1371/journal.pone.0025966
Source: PubMed


Epidemiological research links vitamin D status to various brain-related outcomes. However, few trials examine whether supplementation can improve such outcomes and none have examined effects on cognition. This study examined whether Vitamin D supplementation led to improvements in diverse measures of cognitive and emotional functioning, and hypothesised that supplementation would lead to improvements in these outcomes compared to placebo.
Healthy young adults were recruited to a parallel-arm, double-blind trial conducted at The University of Queensland. Participants were randomly allocated to receive Vitamin D (one capsule daily, containing 5000 IU cholecalciferol) or identical placebo capsule for six weeks. All participants and outcome assessors were blinded to group assignment. Primary outcome measures assessed at baseline and 6 weeks were working memory, response inhibition and cognitive flexibility. Secondary outcomes were: hallucination-proneness, psychotic-like experiences, and ratings of depression, anxiety and anger. 128 participants were recruited, randomised and included in primary analyses (vitamin D n = 63; placebo n = 65). Despite significant increases in vitamin D status in the active group, no significant changes were observed in working memory (F = 1.09; p = 0.30), response inhibition (F = 0.82; p = 0.37), cognitive flexibility (F = 1.37; p = 0.24) or secondary outcomes. No serious adverse effects were reported.
Our findings indicate that vitamin D supplementation does not influence cognitive or emotional functioning in healthy young adults. Future controlled trials in targeted populations of interest are required to determine whether supplementation can improve functioning in these domains. Australian and New Zealand Clinical Trials Registry; ACTRN12610000318088.

Download full-text


Available from: Angela J Dean,
  • Source
    • "This finding seems to contradict the neuropsychological literature since it is commonly accepted that the intracranial volume is positively correlated with the intelligence quotient (IQ) and inversely associated with the risk of Alzheimer disease [6]. However the relationship between vitamin D and cognition has been found thus far only in older adults but not in younger ones [7], and hypovitaminosis D is a condition mostly faced by seniors [1], therefore the latter finding should be evaluated in older adults. We had the opportunity to examine the association of serum 25OHD concentration with intracranial volume among older adults recruited in the 'Gait and Alzheimer Interactions Tracking' (GAIT) study [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D is involved in skeletal and brain health. Recently, serum 25-hydroxyvitamin D (25OHD) concentration was found to be inversely correlated with intracranial volume in younger adults. Since hypovitaminosis D is most common in older adults, our objective was to determine whether this inverse correlation between 25OHD concentration and intracranial volume also occurred in older adults. Cross-sectional study. One hundred and ten Caucasian older community-dwellers (mean, 71.7±5.7 years; 45.5% female) received a blood test and an MRI of the brain at the same period. The intracranial volume and the subvolumes of cerebrospinal fluid, total brain, infratentorial brain, supratentorial brain, total white matter, total gray matter, cortical gray matter and subcortical gray matter were measured using FreeSurfer volumetry on T1-weighted images. Vitamin D insufficiency was defined as serum 25OHD<50nmol/L. Age, gender, body mass index, education level, use of vitamin D supplements, season of evaluation, serum concentrations of calcium and thyroid stimulating hormone were used as covariables in the analysis. We found that participants with vitamin D insufficiency (n=41) had greater intracranial volume than those without (1555.0±1379.2cm(3) versus 1488.0±167.4cm(3), P=0.033). Serum 25OHD concentration was cross-sectionally associated with decreased intracranial volume in mm(3) (unadjusted β=-1194.4, P=0.028), even after adjustment for covariables (adjusted β=-994.3, P=0.048). We found an inverse correlation of serum 25OHD with intracranial volume (r=-0.21, P=0.028) and the volume of white matter (r=-0.20, P=0.033). The other subvolumes did not correlate with serum 25OHD concentration. Serum 25OHD concentration was independently and inversely associated with intracranial volume in older adults. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Maturitas 12/2014; 80(3). DOI:10.1016/j.maturitas.2014.12.011 · 2.94 Impact Factor
  • Source
    • "Bertone-Johnson et al. 2012 [38] Postmenopausal Women with depressive symptoms 36,282 (I 18176, C 18106) 11 Dean et al. 2011 [45] Young healthy adults (University students) 128 (I 63, C 65) 11 Dumville et al. 2006 [43] Older women with seasonal affective disorder 2117 (I 912,C 1205) 11 Gloth et al. 1999 [44] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Efficacy of Vitamin D supplements in depression is controversial, awaiting further literature analysis. Biological flaws in primary studies is a possible reason meta-analyses of Vitamin D have failed to demonstrate efficacy. This systematic review and meta-analysis of Vitamin D and depression compared studies with and without biological flaws. The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature search was undertaken through four databases for randomized controlled trials (RCTs). Studies were critically appraised for methodological quality and biological flaws, in relation to the hypothesis and study design. Meta-analyses were performed for studies according to the presence of biological flaws. The 15 RCTs identified provide a more comprehensive evidence-base than previous systematic reviews; methodological quality of studies was generally good and methodology was diverse. A meta-analysis of all studies without flaws demonstrated a statistically significant improvement in depression with Vitamin D supplements (+0.78 CI +0.24, +1.27). Studies with biological flaws were mainly inconclusive, with the meta-analysis demonstrating a statistically significant worsening in depression by taking Vitamin D supplements (-1.1 CI -0.7, -1.5). Vitamin D supplementation (≥800 I.U. daily) was somewhat favorable in the management of depression in studies that demonstrate a change in vitamin levels, and the effect size was comparable to that of anti-depressant medication.
    Nutrients 04/2014; 6(4):1501-18. DOI:10.3390/nu6041501 · 3.27 Impact Factor
  • Source
    • "When adult rats (6 months old) were administered DHVD3 for 21 days, cognitive function was not altered29. In human young adults, DHVD3 supplementation also did not alter cognitive function30. The conformation of DHVD3 is flexible, and approximately 95% of DHVD3 exists in the non-steroidal and extended 6-s-trans form1531. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that diosgenin, a plant-derived steroidal sapogenin, improved memory and reduced axonal degeneration in an Alzheimer's disease mouse model. Diosgenin directly activated the membrane-associated rapid response steroid-binding receptor (1,25D3-MARRS) in neurons. However, 1,25D3-MARRS-mediated diosgenin signaling was only shown in vitro in the previous study. Here, we aimed to obtain in vivo evidence showing that diosgenin signaling is mediated by 1,25D3-MARRS in the mouse brain. Diosgenin treatment in normal mice enhanced object recognition memory and spike firing and cross-correlation in the medial prefrontal cortex and hippocampal CA1. In diosgenin-treated mice, axonal density and c-Fos expression was increased in the medial prefrontal and perirhinal cortices, suggesting that neuronal network activation may be enhanced. The diosgenin-induced memory enhancement and axonal growth were completely inhibited by co-treatment with a neutralizing antibody for 1,25D3-MARRS. Our in vivo data indicate that diosgenin is a memory-enhancing drug and that enhancement by diosgenin is mediated by 1,25D3-MARRS-triggered axonal growth.
    Scientific Reports 12/2013; 3:3395. DOI:10.1038/srep03395 · 5.58 Impact Factor
Show more